We are considering that the clinical performance of the RUO and IVD of apoA2-i is almost the same, because Sato et al. reported that the AUC value was 0.889 in the previous study, which was investigated in a cross-sectional study using data obtained from the experimental cancer screening using the RUO reagent of apoA2-i. This evidence concerns the gene APOA2 and cancer.